Biomarkers for Early Detection of Hematopoietic Malignancies (R01) | Apply Online

Opportunity Summary:

The Biomarkers for Early Detection of Hematopoietic Malignancies (R01) opportunity (Funding Opportunity Number PA-09-197) is a National Cancer Institute (NCI) research funding announcement under the National Institutes of Health (NIH). Its central aim is to push forward the discovery, development, and rigorous validation of biomarkers that can help identify blood and bone marrow cancers earlier, track how these diseases evolve over time, and improve the ability to estimate a person s risk of developing these malignancies. The announcement is especially focused on applications that address people at elevated risk, where better early-warning tools could make the biggest difference for prevention, monitoring, or earlier intervention.

From a scientific standpoint, the FOA emphasizes two main biomarker use cases. First, it seeks biomarkers for early detection as well as for predicting progression and recurrence of hematopoietic malignancies, with particular attention to high-risk individuals. In practical terms, this includes markers that could flag a developing malignancy before symptoms appear, distinguish which early or precursor conditions are likely to progress, or help identify whether disease is returning after treatment. Second, it encourages biomarkers that support risk assessment for both primary hematopoietic malignancies (first-time cancers) and secondary hematopoietic malignancies (for example, therapy-related or subsequent malignancies that can arise after treatment for another condition). Across both areas, the underlying theme is that biomarkers should be developed with an eye toward real clinical or public health utility, not just exploratory associations.

A notable feature of this opportunity is its strong encouragement of technology and method development that improves how biomarkers are measured. The FOA specifically calls for the development and improvement of technologies and methods for quantitative detection of novel biomarkers linked to hematopoietic malignancies. This highlights an interest in tools that can reliably measure biomarkers at low levels, do so reproducibly across sites or platforms, and potentially be used in settings where screening or longitudinal monitoring is feasible. While the text provided does not list specific platforms, the intent is clearly to support advances that make biomarker detection more sensitive, accurate, scalable, and clinically meaningful.

The funding mechanism is the NIH R01 Research Project Grant, which typically supports more mature, hypothesis-driven projects that are ready for substantial development and validation work. This FOA is described as running in parallel with a companion announcement (PA-09-198) using the R21 Exploratory/Developmental mechanism, which generally targets earlier-stage, higher-risk concepts. Applicants therefore had a pathway choice: use the R01 mechanism for more established approaches with stronger preliminary support and clearer validation plans, or the R21 for earlier exploratory work, while staying within the same overall scientific scope.

In terms of funding availability and award volume, the announcement does not guarantee a set number of awards. Instead, it states that awards are contingent on the availability of funds and the receipt of a sufficient number of meritorious applications. That is a standard NIH structure: applications compete based on scientific merit and program priorities, and final funding depends on NCI budgets and portfolio considerations at the time of award.

Eligibility is broad and includes many organization types. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with and without 501(c)(3) status (with the noted exception language relating to institutions of higher education), state governments, and for-profit organizations other than small businesses. The FOA also lists additional eligible entities such as federal government agencies, Hispanic-serving institutions, non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions. No cost sharing or matching requirement is indicated, meaning applicants were not required to contribute non-federal funds as a condition of the award.

Administrative details in the source data indicate that the opportunity was posted and created on June 1, 2009, with an original and current closing date of September 7, 2012, and an archive date of October 8, 2012. The activity aligns with NIH cancer research assistance listings under CFDA numbers 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research, reflecting its dual emphasis on both reducing risk and improving detection and diagnostic pathways. For full official details, the announcement points to the NIH Grants Guide page (http://grants.nih.gov/grants/guide/pa-files/PA-09-197.html) and provides the NIH Office of Extramural Research webmaster contact for access or linking issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Biomarkers for Early Detection of Hematopoietic Malignancies (R21)

Previous opportunity: Recovery Act Coastal

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 09 197

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 09 197) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 197", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.